Excellent outcomes using a novel reduced intensity conditioning with…
A gentler chemotherapy approach helps older sickle cell patients survive and thrive after bone marrow transplants, addressing a long-standing gap in their treatment options.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
GPND-AI NULISA
A blood test using artificial intelligence can now distinguish between four major forms of dementia with 92% accuracy, offering hope for faster, more precise diagnosis.
Novel or significantly improved treatmentThe clinical landscape of HIF2α inhibitors in oncology
HIF2α inhibitors show expanding promise across multiple cancer types, with growing understanding of how to predict who benefits and overcome drug resistance.
Standard additionBCMA-Targeted Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Three newly approved antibody drugs give doctors practical options for treating advanced multiple myeloma patients who've exhausted other therapies.
Promising but preliminaryOVCA2 acts as an oncogene in pediatric AML by negatively regulating…
Researchers identified a new weakness in pediatric acute myeloid leukemia that could eventually lead to more targeted, effective treatments.